Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults
- Conditions
- Frail Elderly Syndrome
- Interventions
- Dietary Supplement: FisetinDrug: Placebo oral capsule
- Registration Number
- NCT03675724
- Lead Sponsor
- Mayo Clinic
- Brief Summary
This is a pilot study to test the efficacy of the anti-inflammatory drug (Fisetin) in reducing inflammatory factors in blood in elderly adults and to test the efficacy of the drug (Fisetin) in reducing frailty and markers of inflammation, insulin resistance, and bone resorption in elderly adults.
- Detailed Description
To the researchers' knowledge, there are no published studies utilizing Fisetin in alteration of frailty markers. Several studies involve use of Fisetin for its anti-oxidative and anti-apoptotic effects in animal models. Fisetin may reduce oxidative stress, alleviate hyperglycemia, and improve kidney function. No one has evaluated the biologic markers of inflammation and frailty in older adults. The researchers plan to evaluate markers of frailty and markers of inflammation, insulin resistance, and bone resorption while maintaining bone formation in older adults.
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment Fisetin Fisetin 20mg/kg/day, orally for 2 consecutive days Placebo Placebo oral capsule Placebo capsules orally for 2 consecutive days
- Primary Outcome Measures
Name Time Method Decrease in blood inflammation markers Seven Days Percent decrease in blood inflammation markers
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States
Mayo Clinic in Rochester🇺🇸Rochester, Minnesota, United States